. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin. FASEB J. 2001 Jan;15(1):16-18. Epub 2000 Nov 9 PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

  1. Wortmannin is too toxic to be used as a therapeutic, but the idea of using such inhibitors is important to be aware of.

  2. "An interesting paper which shows yet another way of reducing plaque load... as a result of the transgenic work, there are now many hopeful avenues for the drug industry and academics to look for Alzheimer treatments."

This paper appears in the following:

News

  1. Budding RNAi Therapies, APP Protein Interaction Map Impress at Meeting